Shares of Smith & Nephew plc (LON:SN - Get Free Report) crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of GBX 1,045.53 ($14.35) and traded as high as GBX 1,101.50 ($15.12). Smith & Nephew shares last traded at GBX 1,096.50 ($15.05), with a volume of 1,074,849 shares.
Smith & Nephew Trading Up 0.4%
The company has a quick ratio of 0.84, a current ratio of 2.51 and a debt-to-equity ratio of 70.22. The business's fifty day simple moving average is GBX 1,064.34 and its two-hundred day simple moving average is GBX 1,045.53. The company has a market cap of £12.07 billion, a price-to-earnings ratio of 39.64, a PEG ratio of 0.46 and a beta of 0.62.
Insiders Place Their Bets
In other Smith & Nephew news, insider Jeremy (Jez) Maiden bought 1,855 shares of the stock in a transaction dated Thursday, May 1st. The shares were acquired at an average cost of GBX 1,070 ($14.68) per share, for a total transaction of £19,848.50 ($27,238.23). 0.19% of the stock is owned by corporate insiders.
Smith & Nephew Company Profile
(
Get Free Report)
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Smith & Nephew, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Smith & Nephew wasn't on the list.
While Smith & Nephew currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
